Association between vancomycin trough concentration and area under the concentration-time curve in neonates

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 11, 2014, Pages 6454-6461

  Frymoyer, Adam ^a   Hersh, Adam L ^b   El Komy, Mohammed H ^c   Gaskari, Shabnam ^d   Su, Felice ^a   Drover, David R ^a   Van Meurs, Krisa ^a  

^a STANFORD UNIVERSITY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c Beni Suef University   (Egypt)

^d LUCILE PACKARD CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; DOPAMINE; FUROSEMIDE; GENTAMICIN; INDOMETACIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BODY WEIGHT; CLINICAL PHARMACOLOGY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NEWBORN; NEWBORN INTENSIVE CARE; PLASMA CONCENTRATION-TIME CURVE; RETROSPECTIVE STUDY; SERUM; STEADY STATE; VOLUME OF DISTRIBUTION; BIOSYNTHESIS; BLOOD; DOSE RESPONSE; DRUG EFFECTS; GESTATIONAL AGE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MONTE CARLO METHOD; NEONATAL INTENSIVE CARE UNIT; STAPHYLOCOCCAL INFECTIONS;

ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; BODY WEIGHT; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GESTATIONAL AGE; HUMANS; INFANT, NEWBORN; INTENSIVE CARE UNITS, NEONATAL; MALE; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; RETROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; VANCOMYCIN;

EID: 84908302460     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.03620-14     Document Type: Article

References (35)

1. Clark RH, Bloom BT, Spitzer AR, Gerstmann DR. 2006. Reported medication use in the neonatal intensive care unit: data from a large national data set. Pediatrics 117:1979-1987. http://dx.doi.org/10.1542/peds.2005-1707.
2. Boghossian NS, Page GP, Bell EF, Stoll BJ, Murray JC, Cotten CM, Shankaran S, Walsh MC, Laptook AR, Newman NS, Hale EC, McDonald SA, Das A, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. 2013. Late-onset sepsis in very low birth weight infants from singleton and multiple-gestation births. J. Pediatr. 162:1120-1124.e1. http://dx.doi.org/10.1016/j.jpeds.2012.11.089.
3. Stoll BJ, Hansen N, Fanaroff AA, Wright LL, Carlo WA, Ehrenkranz RA, Lemons JA, Donovan EF, Stark AR, Tyson JE, Oh W, Bauer CR, Korones SB, Shankaran S, Laptook AR, Stevenson DK, Papile LA, Poole WK. 2002. Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 110:285-291. http://dx.doi.org/10.1542/peds.110.2.285.
4. Capparelli EV, Lane JR, Romanowski GL, McFeely EJ, Murray W, Sousa P, Kildoo C, Connor JD. 2001. The influences of renal function and maturation on vancomycin elimination in newborns and infants. J. Clin. Pharmacol. 41:927-934. http://dx.doi.org/10.1177/00912700122010898.
5. Shane AL, Hansen NI, Stoll BJ, Bell EF, Sánchez PJ, Shankaran S, Laptook AR, Das A, Walsh MC, Hale EC, Newman NS, Schrag SJ, Higgins RD, Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. 2012. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants. Pediatrics 129:e914-e922. http://dx.doi.org/10.1542/peds.2011-0966.
6. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, Rybak JM, Talan DA, Chambers HF. 2011. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin. Infect. Dis. 52:285-292. http://dx.doi.org/10.1093/cid/cir034.
7. Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. 2004. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin. Pharmacokinet. 43:925-942. http://dx.doi.org/10.2165/00003088-200443130-00005.
8. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Jr, Craig WA, Billeter M, Dalovisio JR, Levine DP. 2009. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin. Infect. Dis. 49:325-327. http://dx.doi.org/10.1086/600877.
9. Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, Cho S, Natale S, Bui I, Tran TM, Capparelli EV. 2013. Improved vancomycin dosing in children using area under the curve exposure. Pediatr. Infect. Dis. J. 32:e155-e163. http://dx.doi.org/10.1097/INF.0b013e318286378e.
10. Frymoyer A, Guglielmo BJ, Hersh AL. 2013. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr. Infect. Dis. J. 32:1077-1079. http://dx.doi.org/10.1097/INF.0b013e318299f75c.
11. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 2003. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349:1157-1167. http://dx.doi.org/10.1056/NEJMra035092.
12. Holford N, Heo YA, Anderson B. 2013. A pharmacokinetic standard for babies and adults. J. Pharm. Sci. 102:2941-2952. http://dx.doi.org/10.1002/jps.23574.
13. Anderson BJ, Holford NH. 2008. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu. Rev. Pharmacol. Toxicol. 48:303-332. http://dx.doi.org/10.1146/annurev.pharmtox.48.113006.094708.
14. Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E. 2012. External evaluation of population pharmacokinetic models of vancomycin in neonates: the transferability of published models to different clinical settings. Br. J. Clin. Pharmacol. 7:1068-1080. http://dx.doi.org/10.1111/j.1365-2125.2012.04406.x.
15. Anderson BJ, Allegaert K, Van den Anker JN, Cossey V, Holford NHG. 2007. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br. J. Clin. Pharmacol. 63:75-84. http://dx.doi.org/10.1111/j.1365-2125.2006.02725.x.
16. Brendel K, Comets E, Laffont C, Mentré F. 2010. Evaluation of different tests based on observations for external model evaluation of population analyses. J. Pharmacokinet. Pharmacodyn. 37:49-65. http://dx.doi.org/10.1007/s10928-009-9143-7.
17. Comets E, Brendel K, Mentré F. 2008. Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: the NPDE add-on package for R. Comput. Methods Programs Biomed. 90:154-166. http://dx.doi.org/10.1016/j.cmpb.2007.12.002.
18. Sheiner LB, Beal S, Rosenberg B, Marathe VV. 1979. Forecasting individual pharmacokinetics. Clin. Pharmacol. Ther. 26:294-305.
19. Fenton TR, Sauve RS. 2007. Using the LMS method to calculate z-scores for the Fenton preterm infant growth chart. Eur. J. Clin. Nutr. 61:1380-1385. http://dx.doi.org/10.1038/sj.ejcn.1602667.
20. Young TE, Mangum B. 2009. Neofax. Thomson Reuters, Montvale, NJ.
21. Pickering LK, Baker C, Kimberlin DW, Long SS (ed). 2012. Red Book: 2012 report of the committee on infectious diseases, 29th ed. American Academy of Pediatrics, Elk Grove Village, IL.
22. Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. 2009. Current recommended dosing of vancomycin for children with invasive methicillinresistant Staphylococcus aureus infections is inadequate. Pediatr. Infect. Dis. J. 28:398-402. http://dx.doi.org/10.1097/INF.0b013e3181906e40.
23. Frymoyer A, Hersh AL, Coralic Z, Benet LZ, Joseph Guglielmo B. 2010. Prediction of vancomycin pharmacodynamics in children with invasive methicillin-resistant Staphylococcus aureus infections: a Monte Carlo simulation. Clin. Ther. 32:534-542. http://dx.doi.org/10.1016/j.clinthera.2010.03.005.
24. Rhodin MM, Anderson BJ, Peters AM, Coulthard MG, Wilkins B, Cole M, Chatelut E, Grubb A, Veal GJ, Keir MJ, Holford NH. 2009. Human renal function maturation: a quantitative description using weight and postmenstrual age. Pediatr. Nephrol. 24:67-76. http://dx.doi.org/10.1007/s00467-008-0997-5.
25. Allegaert K, Anderson BJ, van den Anker JN, Vanhaesebrouck S, de Zegher F. 2007. Renal drug clearance in preterm neonates: relation to prenatal growth. Ther. Drug Monit. 29:284-291. http://dx.doi.org/10.1097/FTD.0b013e31806db3f5.
26. Grimsley C, Thomson AH. 1999. Pharmacokinetics and dose requirements of vancomycin in neonates. Arch. Dis. Child. Fetal Neonatal Ed. 81:F221-F227. http://dx.doi.org/10.1136/fn.81.3.F221.
27. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. 2004. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob. Agents Chemother. 48:1159-1167. http://dx.doi.org/10.1128/AAC.48.4.1159-1167.2004.
28. Neely MN, Youn G, Jones B, Jelliffe RW, Drusano GL, Rodvold KA, Lodise TP. 2014. Are vancomycin trough concentrations adequate for optimal dosing? Antimicrob. Agents Chemother. 58:309-316. http://dx.doi.org/10.1128/AAC.01653-13.
29. Van Hal SJ, Paterson DL, Lodise TP. 2013. Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter. Antimicrob. Agents Chemother. 57:734-744. http://dx.doi.org/10.1128/AAC.01568-12.
30. Sheiner LB, Rosenberg B, Melmon KL. 1972. Modelling of individual pharmacokinetics for computer-aided drug dosage. Comput. Biomed. Res. 5:411-459. http://dx.doi.org/10.1016/0010-4809(72)90071-7.
31. Sheiner LB, Beal SL. 1982. Bayesian individualization of pharmacokinetics: simple implementation and comparison with non-Bayesian methods. J. Pharm. Sci. 71:1344-1348. http://dx.doi.org/10.1002/jps.2600711209.
32. Schumacher GE, Barr JT. 1984. Bayesian approaches in pharmacokinetic decision making. Clin. Pharm. 3:525-530.
33. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. 2011. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann. Pharmacother. 45:757-763. http://dx.doi.org/10.1345/aph.1P634.
34. Berthoin K, Ampe E, Tulkens PM, Carryn S. 2009. Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections. Int. J. Antimicrob. Agents 34:555-560. http://dx.doi.org/10.1016/j.ijantimicag.2009.08.005.
35. Allegaert K, Kuppens M, Mekahli D, Levtchenko E, Vanstapel F, Vanhole C, van den Anker JN. 2012. Creatinine reference values in ELBW infants: impact of quantification by Jaffe or enzymatic method. J. Matern. Fetal Neonatal Med. 25:1678-1681. http://dx.doi.org/10.3109/14767058.2012.657277.